Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 06 Feb 2023
Annual private health insurance premium rise
6 February 2023 - The Australian Government is ensuring Australians get value for money from their private health insurance as the ...
Posted by Michael Wonder on 06 Feb 2023
Sandoz biologics license application for proposed biosimilar denosumab accepted by US FDA
6 February 2023 - Submission supported by comprehensive analytical and clinical data package. ...
Posted by Michael Wonder on 06 Feb 2023
Changes to HPV vaccine dose schedule for young Australians
6 February 2023 - From 6 February 2023 the human papillomavirus vaccine schedule will become a single dose schedule. ...
Posted by Michael Wonder on 05 Feb 2023
Amazon’s RxPass doesn’t yet really compete with Mark Cuban’s Cost Plus Drug Company
3 February 2023 - Amazon is adding RxPass to its pharmacy footprint. Purportedly, it’s competing with Mark Cuban’s Cost Plus Drug ...
Posted by Michael Wonder on 05 Feb 2023
Release of the Strengthening Medicare Taskforce Report
3 February 2023 - The Strengthening Medicare Taskforce Report is now available. ...
Posted by Michael Wonder on 05 Feb 2023
AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
3 February 2023 - AstraZeneca's Imfinzi (durvalumab) has been approved by the MHRA to treat biliary tract cancer in combination ...
Posted by Michael Wonder on 05 Feb 2023
Smoothing Medicare Part D out of pocket costs under the Inflation Reduction Act
3 February 2023 - The Inflation Reduction Act of 2022 marks the first major overhaul of the Medicare Part D prescription ...
Posted by Michael Wonder on 04 Feb 2023
NICE’s new methods reflect society’s values
4 February 2023 - The mission of NICE is to get the best care to patients fast, while ensuring value for ...
Posted by Michael Wonder on 04 Feb 2023
High priced medicine could be our best chance to lower drug prices
3 February 2023 - The best opportunity to rein in skyrocketing drug prices is coming from the most unlikely place – ...
Posted by Michael Wonder on 04 Feb 2023
US FDA approves Takeda’s Takhyzro (lanadelumab-flyo) to prevent hereditary angioedema attacks in children 2 years of age and older
3 February 2023 - Approval supported by extrapolation of efficacy data from the Phase 3 HELP study with additional data from ...
Posted by Michael Wonder on 04 Feb 2023
European Commission approves label expansion of Roche’s Hemlibra to include people with moderate haemophilia A in the EU
1 February 2023 - The approval is based on the HAVEN 6 results, where Hemlibra demonstrated effective bleed control and ...
Posted by Michael Wonder on 03 Feb 2023
Medicare may test policy of paying less for accelerated approval drugs
31 January 2023 - Medicare official hinted Tuesday that Medicare might test a policy of paying less for drugs that ...
Posted by Michael Wonder on 03 Feb 2023
FDA approves sacituzumab govitecan-hziy for HR positive breast cancer
3 February 2023 - Today, the FDA approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences) for patients with unresectable locally advanced or ...
Posted by Michael Wonder on 03 Feb 2023
MHRA approves Rinvoq (upadacitinib monohydrate) as first oral advanced therapy to treat adults with moderately to severely active Crohn's disease
3 February 2023 - This approval for Great Britain marks the first marketing authorisation globally for the use of upadacitinib, a ...
Posted by Michael Wonder on 03 Feb 2023
Medication for opioid addiction is getting easier to access
2 February 2023 - A pandemic experiment in America is about to be made permanent. ...